| Schedule of Segment Reporting Information, by Segment |
The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold. | | | Dermatology | | Pharmaceutical
and
Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended September 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 2,170 | | $ | 350 | | $ | 44,366 | | $ | 46,886 | | | Direct cost of goods | | | (505) | | | - | | | | | | (505) | | | Sales and marketing costs | | | (2,786) | | | - | | | | | | (2,786) | | | Research and development | | | | | | (16,190) | | | | | | (16,190) | | | General and administrative | | | (349) | | | (11,969) | | | | | | (12,318) | | | National Expenses | | | - | | | - | | | (47,690) | | | (47,690) | | | Segment loss from operations | | $ | (1,470) | | $ | (27,809) | | $ | (3,324) | | $ | (32,603) | | | Segment assets | | $ | 7,362 | | $ | 160,038 | | $ | 77,691 | | $ | 245,091 | | | | | | | | Pharmaceutical
and | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended September 30, 2016 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 429 | | $ | 546 | | $ | - | | $ | 975 | | | Direct cost of goods | | | (41) | | | - | | | - | | | (41) | | | Sales and marketing costs | | | (1,244) | | | - | | | - | | | (1,244) | | | Research and development | | | - | | | (8,316) | | | - | | | (8,316) | | | General and administrative | | | (422) | | | (7,198) | | | - | | | (7,620) | | | Segment loss from operations | | $ | (1,278) | | $ | (14,968) | | $ | - | | $ | (16,246) | | | Segment assets | | $ | 2,657 | | $ | 103,225 | | $ | 39,539 | | $ | 145,421 | | | | | Dermatology | | Pharmaceutical
and
Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Nine Months Ended September 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 8,309 | | $ | 1,393 | | $ | 132,563 | | $ | 142,265 | | | Direct cost of goods | | | (1,852) | | | - | | | | | | (1,852) | | | Sales and marketing costs | | | (7,663) | | | - | | | | | | (7,663) | | | Research and development | | | | | | (38,077) | | | | | | (38,077) | | | General and administrative | | | (961) | | | (27,866) | | | | | | (28,827) | | | National Expenses | | | - | | | - | | | (139,219) | | | (139,219) | | | Segment loss from operations | | $ | (2,167) | | $ | (64,550) | | $ | (6,656) | | $ | (73,373) | | | Segment assets | | $ | 7,362 | | $ | 160,038 | | $ | 77,691 | | $ | 245,091 | | | | | | | | Pharmaceutical
and | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Nine Months Ended September 30, 2016 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 1,793 | | $ | 2,072 | | $ | - | | $ | 3,865 | | | Direct cost of goods | | | (365) | | | - | | | - | | | (365) | | | Sales and marketing costs | | | (4,212) | | | - | | | - | | | (4,212) | | | Research and development | | | - | | | (24,559) | | | - | | | (24,559) | | | General and administrative | | | (1,338) | | | (19,864) | | | - | | | (21,202) | | | Segment loss from operations | | $ | (4,122) | | $ | (42,351) | | $ | - | | $ | (46,473) | | | Segment assets | | $ | 2,657 | | $ | 103,225 | | $ | 39,539 | | $ | 145,421 | |
|